L'étude de stabilité (STABILITY)
L'étude de stabilité : résultats du mouvement fonctionnel chez les patients traités avec un dispositif de fusion interépineuse pour des affections dégénératives de la colonne lombaire
This is a prospective, multi-center open-label single arm post-market study where the purpose is to evaluate the effectiveness and safety of the market approved Spinal Simplicity Minuteman G5 MIS Fusion Plate and bone graft material in patients with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication. The indication for the device under study is degenerative conditions of the lumbar spine resulting in back pain with lower extremity symptoms and neurogenic claudication.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Up to 150 subjects will be enrolled and treated at up to 20 study sites. Qualified subjects will be enrolled and treated with the Minuteman G5 Device. Subjects will be seen at 1-, 3-, 6- and 12-months following study treatment.
Key outcome assessments will include gait and balance testing performed using BioMech Lab sensor technology to capture and deliver three-dimensional patient motion data to a mobile device that instantly analyzes, distills, and quantifies the information. Patient reported outcome measures will also be collected to evaluate pain, quality of life and satisfaction. During the primary assessment at 12-months post-treatment subject will be offered a computerized topography (CT) scan to evaluate spinal fusion.
After completion of the Month 12 visit all subjects will be asked to complete annual visits through 5 years, which include collection of PROMs, safety review, and can be completed in person or remote.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Echo Cundiff
- Numéro de téléphone: 913-451-4414
- E-mail: ecundiff@spinalsimplicity.com
Sauvegarde des contacts de l'étude
- Nom: Adam Rogers
- Numéro de téléphone: 913-451-4414
- E-mail: arogers@spinalsimplicity.com
Lieux d'étude
-
-
Georgia
-
Newnan, Georgia, États-Unis, 30265
- Recrutement
- Vista Clinical Research
-
Chercheur principal:
- Sandeep Vaid, MD
-
Contact:
- Debra Helton
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46250
- Recrutement
- Comprehensive Pain & Spine Specialists
-
Chercheur principal:
- Andrew Trobridge, MD
-
Contact:
- Esther Owusu
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Pas encore de recrutement
- University of Kansas Medical Center
-
Contact:
- Manuel Clark
-
Chercheur principal:
- Usman Latif, MD, MBA
-
Sous-enquêteur:
- Dawood Sayed, MD
-
-
Louisiana
-
Slidell, Louisiana, États-Unis, 70458
- Recrutement
- Paradigm Health System
-
Contact:
- Chris RC
- Numéro de téléphone: 985-882-4500
- E-mail: cminnerly@paradigmhealth.net
-
Chercheur principal:
- Neilson Tran, MD
-
-
Minnesota
-
Edina, Minnesota, États-Unis, 55435
- Recrutement
- Nura Precision Pain Management
-
Contact:
- Ken Farmer
-
Chercheur principal:
- R. Scott Stayner, MD
-
-
Oregon
-
Eugene, Oregon, États-Unis, 97404
- Recrutement
- Pacific Sports & Spine
-
Chercheur principal:
- Gregory Moore, MD
-
Contact:
- Katie Fabian
-
-
West Virginia
-
Charleston, West Virginia, États-Unis, 25301
- Recrutement
- Spine & Nerve Center of the Virginias
-
Chercheur principal:
- Timothy Deer, MD
-
Contact:
- Amy Young, RN-RC
-
Sous-enquêteur:
- Christopher Kim, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
A subject must MEET ALL of the following inclusion criteria:
- Be a candidate for Spinal Simplicity Minuteman G5 Fusion Plate device per labeled indication
- Be willing and capable of giving written consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided
- Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand the written informed consent
- Be 18 years of age or older at the time of enrollment
- Have been diagnosed with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication
- Received at least 3 months of non-operative or conservative treatment without significant benefit in the opinion of the Investigator
- Be willing and able to comply with study-related requirements, procedures and visits
- Be on a stable pain medication regimen, as determined by the Investigator, for at least 30 days prior to enrolling in this study.
- Must disclose any unresolved major issues of secondary gain (e.g., social, financial, legal), as determined by the Investigator. Including being involved in an injury claim under current litigation or has a pending or approved worker's compensation claim. Subjects will not be excluded due to secondary gain, but it should be disclosed at Enrollment.
Exclusion Criteria
A subject must NOT MEET ANY of the following exclusion criteria:
- Had previous spinal surgery at the level of intervention (e.g. lumbar fusion, discectomy, Laminectomy) MILD procedure is not considered an exclusion.
- Patient physically unable to perform the Gait and/or Balance tests.
- Current systemic infection or local infection increasing the risk of surgery
- History of medications decreasing bone quality or soft tissue healing in the opinion of the Investigator
- Grade II-V spondylolisthesis
- Significant scoliosis with Cobb angle >10 degrees
- Unremitting back pain in a spinal flexion position
- Active systemic disease that may affect the welfare of the subject in the opinion of the Investigator
- Be concurrently participating in another clinical drug and/or device study that may alter or confound the results of the assessment (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) as determined by the investigator.
- Vertebral osteoporosis or history of vertebral fracture
- Be pregnant/ lactating or plan to become pregnant from study enrollment through 3 months post-operatively. (determined by urine testing unless female subject is surgical sterile or post-menopausal). If female, sexually active and childbearing age, subject must be willing to use a reliable form of birth control through the 3-month visit.
- Malformation or dysplasia of spinous process
- Severe osteoporosis with T score <-2.5 SD
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Surgical Group
patient treated with Minuteman G5 interspinous fusion device 510k cleared for degenerative conditions of the lumbar spine |
The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain (Overall, Back and Leg) using NRS/numeric rating scale
Délai: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
|
Overall pain, as well as back pain when standing/walking and leg pain when standing will be assessed using a numeric rating scale (NRS). The NRS is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable. |
Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
|
|
Oswestry Disability Index (ODI)
Délai: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
|
ODI is a self-reported questionnaire widely used to track changes in a patient's condition over time and evaluate the effectiveness of treatments for low back pain. The ODI consists of 10 sections, each addressing a specific aspect of daily functioning. A higher score indicates greater disability. The final score/index ranges from 0-100 scale. A score of 0-20 reflects minimal disability, 21-40 moderate disability, 41-60 severe disability, 61-80 crippled, and 81-100 bed-bound. |
Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
|
|
PROMIS 29 2.0
Délai: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
|
PROMIS-29 c2.0 is a set of standardized questions that measures 29 items across 7 domains of physical and mental health. PROMIS-29 profile assesses pain intensity using a single 0-10 numeric rating scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable. And seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. Each domain is scored on T-Score Scale ranging between 22.9- 81.6 with a mean of 50 and a standard deviation of 10. |
Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.
|
|
Assessment of Motion using BioMech Lab testing equipment
Délai: Baseline and 1-, 3- and 12-months post implantation.
|
A Primary Objective of this study is to collect real-world functional outcomes assessment of motion following treatment with the market-released Spinal Simplicity Minuteman G5 Device using BioMech Lab equipment to record gait and balance. The BioMech Lab motion analytics system will assess gait and balance via sensors placed before physical testing. |
Baseline and 1-, 3- and 12-months post implantation.
|
|
Zurich Classification Questionnaire (ZCQ)
Délai: Baseline and 1-, 3- 6- and 12-months post implantation; annually out to five years.
|
The ZCQ Symptom Severity, Physical Function and Subject Satisfaction allows subjects to rate their symptoms, function or satisfaction on a scale based on their experience over the past week. Symptom Severity domain evaluates the intensity of symptoms such as pain and numbness. It comprises seven items, each rated on a scale from 1 to 5. Overall symptom score ranges from 7-49; with higher scores indicating more severe symptoms. Physical Function domain assesses the impact of symptoms on daily activities. It includes five items, scored on a 1 to 4 scale. Overall symptom score ranges from 5-20; where higher scores denote greater functional impairment. Subject Satisfaction domain measures patient satisfaction with treatment outcomes. It consists of six items, each rated from 1 to 4, with higher scores reflecting greater dissatisfaction. Overall Satisfaction ranges from 6-24: where higher scores denote greater dissatisfaction. |
Baseline and 1-, 3- 6- and 12-months post implantation; annually out to five years.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Spinal Fusion Assessment based on review of Lumbar Computerized Tomography (CT) Scan
Délai: Collected at 12 months post implantation.
|
The secondary objective is to assess spinal fusion at 12 months post-operative using a Fusion Assessment Scale provided by Spinal Simplicity based on review of Lumbar CT Scan. |
Collected at 12 months post implantation.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Tom Hedman, PhD, Spinal Simplicity
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PDPROJ-4-TP-001-23
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Patients will be deidentified with unique study ID. Any study will be anonymized.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .